| A133 |
Crotedumab Biosimilar（Anti-GCGR Reference Antibody）
Featured
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes. |
.png)
|
| A134 |
Volagidemab Biosimilar（Anti-GCGR Reference Antibody）
Featured
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D). |
.png)
|
| A135 |
Naxitamab Biosimilar（Anti-GD2 Reference Antibody）
Featured
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. |
.png)
|
| A136 |
Lorukafusp alfa Biosimilar（Anti-GD2 Reference Antibody）
Featured
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. |
.png)
|
| A137 |
Ecromeximab Biosimilar（Anti-GD3 Reference Antibody）
Featured
|
Ecromeximab (KM 871; KW 2871) is a mouse-derived IgG-κ chimeric antibody targeting ganglioside GD3. Ecromeximab is expressed by YB2/0 rat hybridoma cells. |
.png)
|
| A138 |
Ponsegromab Biosimilar（Anti-GDF15 / MIC1 Reference Antibody）
Featured
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. |
.png)
|
| A139 |
Apitegromab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. |
.png)
|
| A140 |
Trevogrumab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor). Trevogrumab is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake. |
.png)
|
| A141 |
Landogrozumab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease. |
.png)
|
| DC66745 |
Cbl-b-IN-10
Featured
|
Cbl-b-IN-10 (Compound 463) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 6.0 nM and 3.5 nM, respectively. |
|
| A142 |
Lintuzumab Biosimilar（Anti-Siglec-3 / CD33 Reference Antibody）
Featured
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice. |
.png)
|
| A143 |
NGM120 Biosimilar（Anti-GFRAL Reference Antibody）
Featured
|
|
|
| A144 |
Amgen patent anti-GIPR Biosimilar（Anti-GIPR Reference Antibody）
Featured
|
|
|
| A145 |
Centocor patent anti-GLP-1R Biosimilar(Anti-GLP1R Reference Antibody)
Featured
|
|
|
| A146 |
Cureab patent anti-GP73 Biosimilar(Anti-GOLM1 Reference Antibody)
Featured
|
|
|
| A147 |
Glenzocimab Biosimilar(Anti-GP6 / Glycoprotein-6 Reference Antibody)
Featured
|
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. |
.png)
|
| A148 |
KRN330 Biosimilar(Anti-GPA33 Reference Antibody)
Featured
|
|
|
| A149 |
Minomic patent anti-Glypican 1 Biosimilar(Anti-GPC1 / Glypican-1 Reference Antibody)
Featured
|
|
|
| A150 |
Nih Patent Anti-Glypican-2 Biosimilar(Anti-GPC2 / Glypican 2 Reference Antibody)
Featured
|
|
|
| A151 |
Codrituzumab Biosimilar(Anti-GPC3 / Glypican-3 Reference Antibody)
Featured
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. |
.png)
|
| A153 |
Glembatumumab Biosimilar(Anti-GPNMB Reference Antibody)
Featured
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity. |
.png)
|
| A154 |
DS-6157 Biosimilar(Anti-GPR20 Reference Antibody)
Featured
|
|
|
| A155 |
KHK patent anti-CRTH2 Biosimilar(Anti-GPR44 / PTGDR2 / CD294 Reference Antibody)
Featured
|
|
|
| A156 |
BNC101 Biosimilar(Anti-GPR49 / LGR5 Reference Antibody)
Featured
|
|
|
| A157 |
Multiple seq-one in animal Biosimilar(Anti-GPR73 / PROKR1 Reference Antibody)
Featured
|
|
|
| A158 |
Talquetamab Biosimilar(Anti-GPRC5D Reference Antibody)
Featured
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity. |
.png)
|
| A159 |
Regeneron patent anti-GREM1 Biosimilar(Anti-GREM1 / Gremlin Reference Antibody)
Featured
|
|
|
| A160 |
UCB patent anti-Gremlin-1 Biosimilar（Anti-GREM1 / Gremlin Reference Antibody）
Featured
|
|
|
| A161 |
Indusatumab Biosimilar(Anti-GUCY2C Reference Antibody)
Featured
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody. |
.png)
|
| A162 |
KHK patent anti-Haptoglobin Biosimilar(Anti-Haptoglobin Reference Antibody)
Featured
|
|
|
